60548 Federal Register / Vol. 70, No. 200 / Tuesday, October 18, 2005 / Notices 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Adolescent 

Depression. 

Date: October 28, 2005. 

Time: 12 p.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott Suites, 6711 

Democracy Boulevard, Bethesda, MD 20817. 

Contact Person: Karen Sirocco, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3176, 

MSC 7848, Bethesda, MD 20892, 301–435–

0676, siroccok@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Epigenetic 

Changes in Mouse Skin Tumor 

Susceptibility. 

Date: October 28, 2005. 

Time: 12 p.m. to 1:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Elaine Sierra-Rivera, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6184, 

MSC 7804, Bethesda, MD 20892, 301–435–

1779, riverase@csr.nih.gov. 

Name of Committee: Musculoskeletal, Oral 

and Skin Sciences Integrated Review Group, 

Musculoskeletal Tissue Engineering Study 

Section. 

Date: October 31–November 1, 2005. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Jean Dow Sipe, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4106, 

MSC 7814, Bethesda, MD 20892, 301–435–

1743, sipej@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Conflicts in 

Biological Chemistry and Macromolecular 

Biophysics. 

Date: October 31, 2005. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Holiday Inn Select Bethesda, 8120 

Wisconsin Ave., Bethesda, MD 20814. 

Contact Person: Donald L. Schneider, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4172, 

MSC 7806, Bethesda, MD 20892, (301) 435–

1727, schneidd@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, F–13 

Fellowship. 

Date: October 31–November 1, 2005. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. and/or proposals. 

Place: The Watergate, 2650 Virginia 

Avenue, NW., Washington, DC 20037. 

Contact Person: John C. Pugh, PHD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3114, 

MSC 7808, Bethesda, MD 20892, (301) 435–

2398, pughjohn@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Cancer 

Diagnostic and Treatment SBIR/STTR. 

Date: October 31–November 1, 2005. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Hungyi Shau, PHD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6214, 

MSC 7804, Bethesda, MD 20892, 301–435–

1720, shauhung@csr.nih.gov. 

Name of Committee: Oncological Sciences 

Integrated Review Group, Radiation 

Therapeutics and Biology Study Section. 

Date: October 31–November 1, 2005. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Bo Hong, PHD, Scientific 

Review Administrator, Center for Scientific 

Review, National Institutes of Health, 6701 

Rockledge Drive, Room 6194, MSC 7804, 

Bethesda, MD 20892, 301–435–5879, 

hongb@csr.nih.gov. 

Name of Committee: Bioengineering 

Sciences & Technologies Integrated Review 

Group, Modeling and Analysis of Biological 

Systems Study Section. 

Date: October 31–November 1, 2005 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Malgorzata Klosek, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4188, 

MSC 7849, Bethesda, MD 20892, (301) 435–

2211, klosekm@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Drug 

Discovery and Development SBIR/STTR 

Date: October 31, 2005. 

Time: 8:30 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: One Washington Circle Hotel, One 

Washington Circle, Washington, DC 20037 

Contact Person: Sergei Ruvinov, PHD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4158, 

MSC 7806, Bethesda, MD 20892, 301–435–

1180, ruvinser@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Member 

Conflict: Surgery, Anesthesiology, and 

Trauma. 

Date: October 31, 2005. 

Time: 2 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Roberto J. Matus, MD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5108, 

MSC 7854, Bethesda, MD 20892, 301–435–

2204, matusr@csr.nih.gov. 

(Catalogue of Federal Domestic 

Assistance Program Nos. 93.306, 

Comparative Medicine; 93.333, Clinical 

Research, 93.306, 93.333, 93.337, 

93.393–93.396, 93.837–93.844, 93.846–

93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: October 6, 2005. 

Anthony M. Coelho, Jr., 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 05–20739 Filed 10–17–05; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the Center for Scientific 

Review Special Emphasis Panel, 

October 17, 2005, 1 p.m. to October 17, 

2005, 2 p.m., National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, 

MD 20892 which was published in the 

Federal Register on September 30, 2005, 

70 FR 57304–57305. 

The meeting will be held on October 

13, 2005. The meeting time and location 

remain the same. The meeting is closed 

to the public. 

Dated: October 6, 2005. 

Anthony M. Coelho, Jr., 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 05–20740 Filed 10–17–05; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Toxicology Program (NTP); 

Report on Carcinogens; Status of 

Nominations to the 12th Report on 

Carcinogens (RoC): Request for 

Comments and Nominations of 

Scientific Experts 

AGENCY: National Institute of 

Environmental Sciences (NIEHS), 

National Institutes of Health (NIH), 

HHS. 

Federal Register / Vol. 70, No. 200 / Tuesday, October 18, 2005 / Notices 60549 

ACTION: Request for Comments and 

Nominations of Scientific Experts. 

SUMMARY: The NTP invites public 

comments on an updated list of 

nominations proposed for review in the 

12th RoC and the nomination of 

scientists who have expertise and/or 

knowledge relevant to the evaluation of 

carcinogenicity for these nominations 

(see SUPPLEMENTARY INFORMATION). 

Information on the nominations under 

consideration for the RoC can be 

obtained at the NTP Web site http:// 

ntp.niehs.nih.gov (select ‘‘Report on 

Carcinogens’’) or by contacting Dr. C.W. 

Jameson at the address provided below. 

DATES: Comments and nominations will 

be accepted until November 17, 2005. 

ADDRESSES: All correspondence should 

be directed to Dr. C. W. Jameson, 

National Toxicology Program, Report on 

Carcinogens, 79 Alexander Drive, 

Building 4401, Room 3118, P.O. Box 

12233, Research Triangle Park, NC 

27709; phone: (919) 541–4096, fax: (919) 

541–0144, e-mail: 

jameson@niehs.nih.gov. 

SUPPLEMENTARY INFORMATION: 

Background 

This notice provides an update on the 

current status of and/or additions to the 

list of nominations identified in earlier 

Federal Register notices relevant to the 

12th RoC [69FR28940 (May 19, 2004) 

and 69FR62276 (October 25, 2004)]. All 

but the newly identified nomination of 

formaldehyde were announced in 

earlier Federal Register notices. Any 

additional nominations for the 12th RoC 

or modifications to the nominations in 

the attached table will be announced in 

future Federal Register notices. 

Request for Comments on Nominations 

to the RoC 

The following table identifies the 

nominations that the NTP has under 

consideration for review as either a new 

listing in the RoC or as a change in the 

current listing. These nominations are 

provided with their Chemical Abstracts 

Services (CAS) Registry numbers (where 

available) and pending review action. 

The NTP solicits public input on these 

nominations and asks for relevant 

information concerning their 

carcinogenicity as well as current data 

on production, patterns of use, or 

human exposure. The NTP also invites 

interested parties to identify any 

scientific issues related to the listing of 

a specific nomination in the RoC that 

they feel should be addressed during the 

reviews. Individuals who submitted 

comments in response to the May 19, 

2004 Federal Register (69FR28940) and/ 

or the October 25, 2004 Federal Register 

notice (69FR62276) need not re-submit 

their comments as they are already part 

of the public record. Individuals 

submitting public comments are asked 

to include relevant contact information 

[name, affiliation (if any), address, 

telephone, fax, and e-mail] and 

sponsoring organization, if applicable. 

Written submissions will be made 

available on the NTP Web site as they 

are received (http://ntp.niehs.nih.gov/ 

select ‘‘Report on Carcinogens’’) and 

added to the public record. 

Request for Nominations of Scientific 

Experts 

The NTP solicits nominations of 

scientists who have expertise and/or 

knowledge relevant to the evaluation of 

carcinogenicity for the selected 

nominations. These scientists should 

have expertise in various aspects of 

toxicology, epidemiology, 

carcinogenesis, or other relevant areas of 

science (e.g., genetic toxicity, 

metabolism, etc.) and/or experience 

with the agent being reviewed. The 

experts may be used to write and/or 

review the background documents 

prepared on selected nominations. 

Nominations of scientists should 

include contact information for the 

nominee [name, affiliation (if any), 

address, telephone, fax, and e-mail], the 

specific nominated agent(s) (listed in 

the table below) for which they are 

being recommended as an expert, and a 

curriculum vitae (if possible). Contact 

information for the nominator must also 

be provided. 

Additional Nominations Encouraged 

The NTP solicits and encourages the 

broadest participation from interested 

individuals or parties in nominating 

agents, substances, or mixtures for 

review for future RoCs. Nominations 

should contain a rationale for review. 

Appropriate background information 

and relevant data [e.g., journal articles, 

NTP Technical Reports, International 

Agency for Research on Cancer (IARC) 

listings, exposure surveys, release 

inventories, etc.] that support the review 

of a nomination should be provided or 

referenced when possible. Contact 

information for the nominator should 

also be included [name, affiliation (if 

any), address, telephone, fax, and email]. 

Background Information on the Report 

on Carcinogens 

The RoC is a congressionally 

mandated document [Section 301(b)(4) 

of the Public Health Services Act, 42 

U.S.C. 241(b)(4)], published by the 

Secretary of Health and Human Services 

(HHS), that identifies agents, 

substances, mixtures, or exposure 

circumstances (collectively referred to 

as ‘‘substances’’) that may pose a 

carcinogenic hazard to human health. 

The Secretary, HHS, has delegated 

responsibility for preparing the draft 

report to the NTP. Substances are listed 

in the RoC as either known to be a 

human carcinogen or reasonably 

anticipated to be a human carcinogen. 

Review of nominations (substances that 

are under consideration for listing or 

removing from the RoC) involves a 

multi-step scientific review process 

with opportunity for public comment. 

Dated: October 6, 2005. 

Samuel H. Wilson, 

Deputy Director, National Institute of 

Environmental Health Sciences. 

STATUS OF NOMINATIONS TO BE REVIEWED FOR THE REPORT ON CARCINOGENS

Nomination/CAS No. Primary uses or exposures Nominator Basis for nomination Status 

1 Herbal remedies containing aristolochic acid.

*Note—this nomination 

was previously identified 

as ‘‘Aristolochia-Related 

Herbal Remedies’’.

Several Aristolochia species (notably A. contorta, 

A. debilis, A. fangchi 

and A. manshuriensis) 

have been used in traditional Chinese medicine 

as antirheumatics, as 

diuretics, in the treatment of edema, and for 

other conditions such as 

hemorrhoids, coughs, 

and asthma.

NIEHS ............................... Herbal remedies containing the plant genus 

Aristolochia: IARC 2 finding of sufficient evidence 

of carcinogenicity in humans (IARC Monograph 

Vol. 82, 2002).

Review for possible listing 

in 12th RoC. 

60550 Federal Register / Vol. 70, No. 200 / Tuesday, October 18, 2005 / Notices 

STATUS OF NOMINATIONS TO BE REVIEWED FOR THE REPORT ON CARCINOGENS—Continued 

Nomination/CAS No. Primary uses or exposures Nominator Basis for nomination Status 

Aristolochic Acid ................ Aristolochic acid, the principle extract from 

Aristolochia, is a mixture 

of nitrophenanthrene 

carboxylic acids.

NIEHS ............................... Naturally occurring mixtures of aristolochic 

acids: IARC 2 finding of 

sufficient evidence of 

carcinogenicity in animals and limited evidence in humans (IARC 

Monograph Vol. 82, 

2002).

Review for possible listing 

in 12th RoC. 

Asphalt fumes .................... Asphalt is a petroleum 

product used in paving 

and roofing operations. 

Asphalt fumes are a 

cloud of small particles 

generated after volatilization of asphalt aggregates.

Private Individual ............... Human epidemiological 

studies have reported an 

increased risk of lung 

cancer among workers 

exposed to asphalt 

fumes and asphalt 

fumes caused skin tumors in experimental 

animals. Additionally, 

known human carcinogens (polycyclic aromatic hydrocarbons or 

PAHs) have been found 

in asphalt fumes.

Defer review of nomination 

until the 13th RoC. 

Atrazine (192–24–9) .......... Atrazine is an herbicide 

used to control grass 

and broad-leaved 

weeds. Atrazine has 

been detected at levels 

that exceeded or approached the maximum 

contaminant level (MCL) 

for atrazine in 200 community surface drinking 

water systems.

NIEHS ............................... IARC 2 finding of sufficient 

evidence of carcinogenicity in animals 

(IARC Monograph Vol. 

73, 1999).

Defer review of nomination 

until the 13th RoC. 

Benzofuran (271–89–6) ..... Benzofuran is produced by 

isolation from coal-tar 

oils. Benzofuran is used 

in the manufacture of 

coumarone-indene resins, which harden when 

heated and are used to 

make floor tiles and 

other products.

NIEHS ............................... Results of a NTP bioassay 

(NTP Technical Report 

370, 1989) 3, which reported clear evidence of 

carcinogenicity in male 

and female mice and 

some evidence of carcinogenicity in female 

rats.

Defer review of nomination 

until the 13th RoC. 

Captafol (2425–06–01) ...... Captafol is a fungicide that 

has been widely used 

since 1961 for the control of fungal diseases in 

fruits, vegetables, and 

some other plants. Use 

of captafol in the United 

States was banned in 

1999.

NIEHS ............................... IARC 2 finding of sufficient 

evidence of carcinogenicity in animals 

(IARC Monograph Vol. 

53, 1991). IARC also 

noted that captafol is 

positive in many genetic 

assays including the invivo assay for dominant 

lethal mutation.

Review for possible listing 

in 12th RoC. 

1 Cobalt-tungsten carbide 

powders and hard metals.

*Note—This nomination 

was previously identified 

as ‘‘Cobalt/TungstenCarbide Hard Metal 

Manufacturing’’.

Cobalt-tungsten carbide 

hard-metals are manufactured by a process of 

powder metallurgy from 

tungsten and carbon 

(tungsten carbide), and 

small amounts of other 

metallic compounds 

using cobalt as a binder. 

They are used to make 

cutting and grinding 

tools, dies, and wear 

products for a broad 

spectrum of industries 

including oil and gas 

drilling, and mining.

NIEHS ............................... Recent human cancer 

studies on the hard 

metal manufacturing industry showing an association between exposure to hard metals (cobalt tungsten-carbide) 

and lung cancer.

Review for possible listing 

in 12th RoC. 

Federal Register / Vol. 70, No. 200 / Tuesday, October 18, 2005 / Notices 60551 

STATUS OF NOMINATIONS TO BE REVIEWED FOR THE REPORT ON CARCINOGENS—Continued 

Nomination/CAS No. Primary uses or exposures Nominator Basis for nomination Status 

Di (2-ethylhexyl) phthalate 

(DEHP) (117–81–7).

DEHP is mainly used as a 

plasticizer in polyvinyl 

chloride (PVC) resins for 

fabricating flexible vinyl 

products. PVC resins 

have been used to manufacture toys, dolls, vinyl 

upholstery, tablecloths, 

and many other products.

Private Individual ............... Currently listed in the RoC 

as reasonably anticipated to be a human 

carcinogen.

IARC 2 reclassification as 

not classifiable as to its 

carcinogenicity to humans (Group 3) (IARC 

Monograph Vol. 77, 

2000). IARC stated that 

there was sufficient evidence for the carcinogenicity in experimental 

animals; however, the 

mechanism for liver 

tumor involves 

peroxisome proliferation 

that is not relevant to 

humans.

Review for possible removal of listing in 12th 

RoC. 

Etoposide in combination 

with cisplatin and 

bleomycin.

Etoposide in combination 

with cisplatin and 

bleomycin is used to 

treat testicular germ cell 

cancers.

NIEHS ............................... IARC 2 finding of sufficient 

evidence of carcinogenicity in humans 

(IARC Monograph Vol. 

76, 2000).

Review for possible listing 

in 12th RoC. 

Etoposide (33419–42–0) ... Etoposide is a DNA 

topoisomerase II inhibitor used in chemotherapy for non-Hodgkin’s lymphoma, smallcell lung cancer, testicular cancer, lymphomas, 

and a variety of childhood malignancies.

NIEHS ............................... IARC 2 finding of limited 

evidence of carcinogenicity in humans 

(IARC Monograph Vol. 

76, 2000).

Review for possible listing 

in 12th RoC. 

Formaldehyde (50–00–0) .. Formaldehyde is primarily 

used in the production of 

resins that are used in 

the production of many 

different products including plastics, adhesives 

and binders for wood 

products, pulp and 

paper, synthetic fibers, 

and in textile finishing. It 

is also used as a disinfectant and preservative and as an intermediate for many industrial chemicals.

NIEHS ............................... Formaldehyde (gas) is currently listed in the RoC 

as reasonably anticipated to be a human 

carcinogen. Nominated 

for reconsideration 

based on the 2004 

IACR 2 review, which 

concluded that there 

was sufficient evidence 

for the carcinogenicity of 

formaldehyde in humans 

(IARC Monograph Vol. 

88, 2004).

Review for possible reclassification of listing status 

in 12th RoC. 

60552 Federal Register / Vol. 70, No. 200 / Tuesday, October 18, 2005 / Notices 

STATUS OF NOMINATIONS TO BE REVIEWED FOR THE REPORT ON CARCINOGENS—Continued 

Nomination/CAS No. Primary uses or exposures Nominator Basis for nomination Status 

1 Certain Glass Wool Fibers.

*Note—This nomination 

was previously identified 

as ‘‘Glass wool (respirable size): Two nominations: (1) Insulation 

glass wool fibers, and 

(2) Special purpose 

glass fibers’’.

Glass wool fibers, which 

are a type of synthetic 

vitreous fibers, are an 

inorganic fibrous material manufactured primarily from glass and 

processed inorganic oxides. The composition of 

these fibers may vary 

substantially because of 

differences in end-use, 

manufacturing requirements, and biopersistence considerations. 

The major uses of glass 

wool are in thermal, 

electrical, and acoustical 

insulation, weatherproofing, and filtration 

media. Some glass wool 

fibers (special purpose 

fibers) are used for highefficiency air filtration 

media, and acid battery 

separators.

North American Insulation 

Manufacturers Association nominated glass 

wool (respirable size) for 

delisting.

NIEHS recommended that 

the nomination be defined as ‘‘certain glass 

wool fibers’’ because of 

the considerable differences in the composition of glass wool fibers.

Glass wool (respirable 

size) is currently listed in 

the RoC as reasonably 

anticipated to be a 

human carcinogen.

Insulation glass wool: 

IARC 2 finding of limited 

evidence of carcinogenicity in animals and 

evaluation as not classifiable as to its carcinogenicity to humans 

(Group 3) (IARC Monograph Vol. 81, 2002).

Special-purpose glass fibers: IARC 2 finding of 

sufficient evidence of 

carcinogenicity in animals (IARC Monograph 

Vol. 81, 2002).

Review for possible listing 

in 12th RoC. 

Metalworking Fluids ........... Metal working fluids are 

complex mixtures that 

may contain mixtures of 

oil, emulsifiers, anti-weld 

agents, corrosion inhibitors, extreme pressure 

additives, buffers 

biocides, and other additives. They are used to 

cool and lubricate tools 

and working surfaces in 

a variety of industrial 

machining and grinding 

operations.

NIEHS ............................... Recent human cancer 

studies of metal working 

fluids that show an association between exposure to these materials 

and cancer at several 

tissue sites.

Review for possible listing 

in 12th RoC. 

ortho-Nitrotoluene (88–72–

2).

ortho-Nitrotoluene is used 

to synthesize agricultural 

and rubber chemicals, 

azo and sulfur dyes, and 

dyes for cotton, wool, 

silk, leather, and paper.

NIEHS ............................... Results of a NTP bioassay 

(NTP Technical Report 

504, 2002) 3, which reported clear evidence of 

carcinogenicity in rats 

and mice.

Review for possible listing 

in 12th RoC. 

Oxazepam (604–75–1) ...... Oxazepam is a 

benzodiazepine used 

extensively since the 

1960s for the treatment 

of anxiety and insomnia 

and in the control of 

symptoms of alcohol 

withdrawal.

NIEHS ............................... Results of a NTP bioassay 

(NTP Technical Report 

443, 1993) 3, which reported clear evidence of 

carcinogenicity in male 

and female mice.

Defer review of nomination 

until the 13th RoC. 

Riddelliine (23246–96–0) .. Riddelliine is found in 

class of plants growing 

in western United 

States. Cattle, horses, 

and sheep ingest these 

toxic plants. Residues 

have been found in milk 

and honey.

NIEHS ............................... Results of a NTP bioassay 

(NTP Technical Report 

508, 2003) 3, which reported clear evidence of 

carcinogenicity in male 

and female rats and 

mice.

Review for possible listing 

in 12th RoC. 

Styrene (100–42–5) ........... Styrene is used in the production of polystyrene, 

acrylonitrile-butadienestyrene resins, styrenebutadiene rubbers and 

latexes, and unsaturated 

polystyrene resins.

Private Individual ............... IARC 2 finding of limited 

evidence of carcinogenicity in animals and 

limited evidence of carcinogenicity in humans 

(IARC Monograph Vol. 

82, 2002).

Review for possible listing 

in 12th RoC. 

Federal Register / Vol. 70, No. 200 / Tuesday, October 18, 2005 / Notices 60553 

STATUS OF NOMINATIONS TO BE REVIEWED FOR THE REPORT ON CARCINOGENS—Continued 

Nomination/CAS No. Primary uses or exposures Nominator Basis for nomination Status 

Talc (Two nominations) .....

(1) Cosmetic talc ...............

(2) Occupational exposure 

to talc.

Talc occurs in various geological settings around 

the world. Exposure to 

general population occurs through use of 

products such as cosmetics. Occupational exposure occurs during 

mining, milling, and 

processing.

NIEHS ............................... The NTP deferred consideration of listing talc 

(asbestiform and nonasbestiform talc) in the 

10th RoC because its 

2000 review of talc 

found that there has 

been considerable confusion over the mineral 

nature and consequences of exposure 

to talc, both containing 

asbestiform fibers and 

not containing 

asbestiform fibers. It has 

become evident that the 

literature on both forms 

of talc, with a few exceptions, provides an inadequate characterization of the actual materials under study to enable one to reach definitive conclusions concerning the specific substances responsible for 

the range of adverse 

health outcomes reported.

Withdrawn from review. 

Teniposide (29767–20–2) Teniposide is a DNA 

topoisomerase II inhibitors used mainly in the 

treatment of adult and 

childhood leukemia.

NIEHS ............................... IARC 2 finding of limited 

evidence of carcinogenicity in humans 

(IARC Monograph Vol. 

76, 2000).

Review for possible listing 

in 12th RoC. 

Vinyl Mono-Halides as a 

class.

Vinyl halides are used in 

the production of polymers and copolymers. 

Vinyl bromide is mainly 

used in polymers as a 

flame retardant and in 

the production of 

monoacrylic fibers for 

carpet-backing materials. Vinyl chloride is 

used to produce polyvinyl chloride and copolymers. Vinyl fluoride 

is used in the production 

of polyvinyl fluoride, 

which when laminated 

with aluminum, steel and 

other materials, is used 

as a protective surface 

for the exteriors of residential and commercial 

buildings.

NIEHS ............................... Vinyl fluoride and vinyl 

bromide are currently 

listed in the RoC as reasonably anticipated to 

be a human carcinogen 

and vinyl chloride is currently listed in the RoC 

as a known to be a 

human carcinogen.

Vinyl mono-halides: Structural similarities and 

common mechanisms of 

tumor formation.

Defer review of nomination 

until the 13th RoC. 

1 Nomination has been redefined based on public comments received from earlier Federal Register notices and/or review of the literature. 2 International Agency for Research on Cancer (IARC). IARC Monographs are available from http://monographs.iarc.fr/. 3 NTP Technical Reports are available at http://ntp.niehs.nih.gov/ see ‘‘NTP Study Reports.’’

60554 Federal Register / Vol. 70, No. 200 / Tuesday, October 18, 2005 / Notices 

[FR Doc. 05–20729 Filed 10–17–05; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[FEMA–1605–DR] 

Alabama; Amendment No. 7 to Notice 

of a Major Disaster Declaration 

AGENCY: Federal Emergency 

Management Agency, Emergency 

Preparedness and Response Directorate, 

Department of Homeland Security. 

ACTION: Notice. 

SUMMARY: This notice amends the notice 

of a major disaster declaration for the 

State of Alabama (FEMA–1605–DR), 

dated August 29, 2005, and related 

determinations. 

EFFECTIVE DATE: October 5, 2005. 

FOR FURTHER INFORMATION CONTACT: 

Magda Ruiz, Recovery Division, Federal 

Emergency Management Agency, 

Washington, DC 20472, (202) 646–2705. 

SUPPLEMENTARY INFORMATION: The notice 

of a major disaster declaration for the 

State of Alabama is hereby amended to 

include the following area among those 

areas determined to have been adversely 

affected by the catastrophe declared a 

major disaster by the President in his 

declaration of August 29, 2005: Marengo 

County for Individual Assistance 

(already designated for Public 

Assistance.) 

(The following Catalog of Federal Domestic 

Assistance Numbers (CFDA) are to be used 

for reporting and drawing funds: 97.030, 

Community Disaster Loans; 97.031, Cora 

Brown Fund Program; 97.032, Crisis 

Counseling; 97.033, Disaster Legal Services 

Program; 97.034, Disaster Unemployment 

Assistance (DUA); 97.046, Fire Management 

Assistance; 97.048, Individuals and 

Households Housing; 97.049, Individuals and 

Households Disaster Housing Operations; 

97.050 Individuals and Households ProgramOther Needs, 97.036, Public Assistance 

Grants; 97.039, Hazard Mitigation Grant 

Program.) 

R. David Paulison, 

Acting Under Secretary, Emergency 

Preparedness and Response, Department of 

Homeland Security. 

[FR Doc. 05–20770 Filed 10–17–05; 8:45 am] 

BILLING CODE 9110–10–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[FEMA–1603–DR] 

Louisiana; Amendment No. 4 to Notice 

of a Major Disaster Declaration 

AGENCY: Federal Emergency 

Management Agency, Emergency 

Preparedness and Response Directorate, 

Department of Homeland Security. 

ACTION: Notice. 

SUMMARY: This notice amends the notice 

of a major disaster declaration for the 

State of Louisiana (FEMA–1603–DR), 

dated August 29, 2005, and related 

determinations. 

EFFECTIVE DATE: October 7, 2005. 

FOR FURTHER INFORMATION CONTACT: 

Magda Ruiz, Recovery Division, Federal 

Emergency Management Agency, 

Washington, DC 20472, (202) 646–2705. 

SUPPLEMENTARY INFORMATION: The notice 

of a major disaster declaration for the 

State of Louisiana is hereby amended to 

include the following areas among those 

areas determined to have been adversely 

affected by the catastrophe declared a 

major disaster by the President in his 

declaration of August 29, 2005: 

All parishes in the State of Louisiana are 

eligible to apply for assistance under the 

Hazard Mitigation Grant Program. 

(The following Catalog of Federal Domestic 

Assistance Numbers (CFDA) are to be used 

for reporting and drawing funds: 97.030, 

Community Disaster Loans; 97.031, Cora 

Brown Fund Program; 97.032, Crisis 

Counseling; 97.033, Disaster Legal Services 

Program; 97.034, Disaster Unemployment 

Assistance (DUA); 97.046, Fire Management 

Assistance; 97.048, Individuals and 

Households Housing; 97.049, Individuals and 

Households Disaster Housing Operations; 

97.050 Individuals and Households 

Program—Other Needs, 97.036, Public 

Assistance Grants; 97.039, Hazard Mitigation 

Grant Program.) 

R. David Paulison, 

Acting Under Secretary, Emergency 

Preparedness and Response, Department of 

Homeland Security. 

[FR Doc. 05–20769 Filed 10–17–05; 8:45 am] 

BILLING CODE 9110–10–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[FEMA–1607–DR] 

Louisiana; Amendment No. 7 to Notice 

of a Major Disaster Declaration 

AGENCY: Federal Emergency 

Management Agency, Emergency 

Preparedness and Response Directorate, 

Department of Homeland Security. 

ACTION: Notice. 

SUMMARY: This notice amends the notice 

of a major disaster declaration for the 

State of Louisiana (FEMA–1607–DR), 

dated September 24, 2005, and related 

determinations. 

EFFECTIVE DATE: October 7, 2005. 

FOR FURTHER INFORMATION CONTACT: 

Magda Ruiz, Recovery Division, Federal 

Emergency Management Agency, 

Washington, DC 20472, (202) 646–2705. 

SUPPLEMENTARY INFORMATION: The notice 

of a major disaster declaration for the 

State of Louisiana is hereby amended to 

include the following areas among those 

areas determined to have been adversely 

affected by the catastrophe declared a 

major disaster by the President in his 

declaration of September 24, 2005: 

Evangeline, Sabine, St. Landry, and Vernon 

Parishes for Public Assistance [Categories C–

G] (already designated for Individual 

Assistance and debris removal and 

emergency protective measures [Categories A 

and B] under the Public Assistance program, 

including direct Federal assistance.) 

De Soto, Natchitoches, and Rapides 

Parishes for Public Assistance [Categories C–

G] (already designated for debris removal and 

emergency protective measures [Categories A 

and B] under the Public Assistance program, 

including direct Federal assistance.) 

(The following Catalog of Federal Domestic 

Assistance Numbers (CFDA) are to be used 

for reporting and drawing funds: 97.030, 

Community Disaster Loans; 97.031, Cora 

Brown Fund Program; 97.032, Crisis 

Counseling; 97.033, Disaster Legal Services 

Program; 97.034, Disaster Unemployment 

Assistance (DUA); 97.046, Fire Management 

Assistance; 97.048, Individuals and 

Households Housing; 97.049, Individuals and 

Households Disaster Housing Operations; 

97.050 Individuals and Households 

Program—Other Needs, 97.036, Public 

Assistance Grants; 97.039, Hazard Mitigation 

Grant Program.) 

R. David Paulison, 

Acting Under Secretary, Emergency 

Preparedness and Response, Department of 

Homeland Security. 

[FR Doc. 05–20773 Filed 10–17–05; 8:45 am] 

BILLING CODE 9110–10–P